Comprehensive economic value evaluation of adding tislelizumab to first-line chemotherapy for patients with extensive-stage small cell lung cancer in China
Tislelizumab plus chemotherapy could be considered cost-effective first-line therapy for patients with untreated ES-SCLC patients compared with chemotherapy alone from the perspective of Chinese health-care system.
Authors
- Shuo Kang (ORCID: https://orcid.org/0000-0002-8690-4259)
- Shan Zhao
Institutions
- Hebei Medical University (CN)
- Second Hospital of Hebei Medical University (CN)
Publication Details
- Journal
- Expert Review of Pharmacoeconomics & Outcomes Research
- Published
- 2025-03-27
- DOI
- https://doi.org/10.1080/14737167.2025.2483423
- Citations
- 2
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 2.09